摘要
目的:探讨卡托普利联合个性化康复治疗心脏瓣膜病合并心力衰竭的临床疗效。方法:选取2016年1月至2018年5月三河市医院收治的心脏瓣膜病合并心力衰竭患者120例,按照就诊顺序分组,单号为观察组,双号为对照组,每组60例。观察组患者给予卡托普利联合个性化康复治疗,对照组患者仅给予卡托普利治疗。观察两组患者的临床疗效,治疗前后心功能指标[左心室舒张末期内径(LVEDD)和左心室舒张末期容积(LVEDV)、左心室射血分数(LVEF)和左心室收缩末期容积(LVESV)]、血浆B型利钠肽(BNP)、心肌肌钙蛋白Ⅰ(cTnⅠ)及尿酸(UA)水平,左心室扩大、左心房扩大及室性心律失常的发生情况和不良反应发生情况。结果:治疗后,观察组患者的LEVDD、LVEDV、LVEF及LVESV水平明显优于对照组,差异均有统计学意义(P<0.05);治疗后,观察组患者的血浆BNP、cTnⅠ及UA水平明显低于对照组,差异均有统计学意义(P<0.05);观察组患者的左心室扩大、左心房扩大及室性心律失常的发生率明显低于对照组,差异均有统计学意义(P<0.05);观察组患者的总有效率为95.0%(57/60),明显高于对照组的53.3%(32/60),差异有统计学意义(P<0.05);观察组患者的不良反应发生率为5.0%(3/60),明显低于对照组的26.7%(16/60),差异有统计学意义(P<0.05)。结论:卡托普利联合个性化康复治疗心脏瓣膜病合并心力衰竭的疗效良好,且安全性高。
OBJECTIVE: To probe into the clinical efficacy of captopril combined with individualized rehabilitation in treatment of heart valvular disease complicated with heart failure. METHODS: Totally 120 patients heart valvular disease complicated with heart failure admitted into Jan. 2016 to May 2018 were extracted to be divided into the observation group(single number) and the control group(double number) via the admission sequence, 60 cases in each. Patients in the observation group were treated with captopril combined with individualized rehabilitation, while the control group received captopril alone. The clinical efficacy, cardiac function indicators [left ventricular end-diastolic diameter(LVEDD), left ventricular end-diastolic volume(LVEDV), left ventricular ejection fraction(LVEF), left ventricular end-systolic volume(LVESV)], plasma type B Natriuretic peptide(BNP), cardiac troponin Ⅰ(cTnⅠ) and uric acid(UA) levels, left ventricular enlargement, left atrial enlargement and ventricular arrhythmia before and after treatment and adverse drug reactions of two groups were observed. RESULTS: After treatment, the levels of LEVDD, LVEDV, LVEF and LVESV in the observation group were significantly better than those in the control group, with statistically significant differences(P<0.05). The levels of BNP, cTnⅠ and UA in the observation group were significantly lower than those in the control group, with statistically significant differences(P<0.05). The incidence of left ventricular dilatation, left atrial dilatation and ventricular arrhythmia in the observation group was significantly lower than that in the control group,with statistically significant differences(P<0.05). The total effective rate of the observation group was 95.0%(57/60), significantly higher than that of the control group(53.3%,32/60), and the difference was statistically significant(P<0.05). The incidence of adverse drug reactions in the observation group was 5.0%(3/60), significantly lower than that in the control group(26.7%,16/60), and the difference was statistically significant(P<0.05). CONCLUSIONS: The efficacy of captopril combined with individualized rehabilitation in treatment of heart valvular disease complicated with heart failure is significant with higher safety.
作者
刘金明
左征
李红娟
李莉
屈艳
LIU Jinming;ZUO Zheng;LI Hongjuan;LI Li;QU Yan(Dept.of Internal Medicine-Cardiovascular,Sanhe Hospital,Hebei Sanhe 065200,China)
出处
《中国医院用药评价与分析》
2019年第6期683-685,共3页
Evaluation and Analysis of Drug-use in Hospitals of China
基金
河北省卫生厅科研基金项目(No.20181467)
关键词
心脏瓣膜病
卡托普利
心力衰竭
临床疗效
Heart valvular disease
Captopril
Heart failure
Clinical efficacy
